# Towards a quantitative understanding of tumor evolution

> **NIH NIH R35** · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2022 · $952,560

## Abstract

ABSTRACT
Cancers are dynamic biological entities whose clonal architecture can change under strong selection pressures,
such as exposure to therapy. As tumors progress through different stages, they coevolve with stromal
populations, which in aggregate constitutes a significant challenge in assessing the potential value of new
therapeutic strategies. Recent discoveries by us and other groups have provided a glimpse of the complexity of
the clonal architecture of many tumors, their dynamics under therapy, and their interactions with the immune
system. In most tumors, several sub-clonal populations simultaneously co-exist, and initially minor clones play a
dominant role in subsequent phases of the tumor’s evolution. As clonal and stromal heterogeneity emerge as
driving forces underlying cancer progression and therapeutic failure, there is a critical need for uncovering the
quantitative fundamental principles underlying the evolution of tumors and their dynamic interaction with their
microenvironment. My recent work has shown that tumor evolution does not proceed in a stochastic fashion but
through a highly structured process, and that future dominant subclones can both be identified and targeted. The
quantitative approaches developed by my group in the last few years are particularly tailored to elucidate the
evolutionary patterns of clonal systems under strong selection. The central hypothesis of this proposal is that (1)
tumor and stroma coevolve in an orchestrated fashion, (2) seeding clones can be identified through genomic and
single cell longitudinal sampling, (3) these clones can be targeted, and (4) in order to characterize these clones
we need to develop new quantitative approaches. The overarching goal of the present proposal is to uncover the
mechanisms by which small tumor and stromal populations coevolve and drive tumor progression and the
emergence of drug resistance, using glioblastoma as a paradigm. Quantitative approaches and fundamental
principles of tumor evolution derived from this research will then be applied to other tumor types.

## Key facts

- **NIH application ID:** 10454356
- **Project number:** 5R35CA253126-02
- **Recipient organization:** COLUMBIA UNIVERSITY HEALTH SCIENCES
- **Principal Investigator:** Raul Rabadan
- **Activity code:** R35 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $952,560
- **Award type:** 5
- **Project period:** 2021-08-01 → 2028-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10454356

## Citation

> US National Institutes of Health, RePORTER application 10454356, Towards a quantitative understanding of tumor evolution (5R35CA253126-02). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10454356. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*